Literature DB >> 16698750

Prospective evaluation of fluorouracil chemotherapy based on the genetic makeup of colorectal cancer.

J M Carethers1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16698750      PMCID： PMC1856230          DOI： 10.1136/gut.2005.085274

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  26 in total

Review 1.  Colorectal cancer prevention and treatment.

Authors:  C R Boland; F A Sinicrope; D E Brenner; J M Carethers
Journal:  Gastroenterology       Date:  2000-02       Impact factor: 22.682

2.  Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer.

Authors:  H Elsaleh; D Joseph; F Grieu; N Zeps; N Spry; B Iacopetta
Journal:  Lancet       Date:  2000-05-20       Impact factor: 79.321

3.  Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer.

Authors:  R Gryfe; H Kim; E T Hsieh; M D Aronson; E J Holowaty; S B Bull; M Redston; S Gallinger
Journal:  N Engl J Med       Date:  2000-01-13       Impact factor: 91.245

4.  Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis.

Authors:  M Guidoboni; R Gafà; A Viel; C Doglioni; A Russo; A Santini; L Del Tin; E Macrì; G Lanza; M Boiocchi; R Dolcetti
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

5.  Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.

Authors:  R Jover; P Zapater; A Castells; X Llor; M Andreu; J Cubiella; V Piñol; R M Xicola; L Bujanda; J M Reñé; J Clofent; X Bessa; J D Morillas; D Nicolás-Pérez; A Payá; C Alenda
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

6.  p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma.

Authors:  H Elsaleh; B Powell; P Soontrapornchai; D Joseph; F Goria; N Spry; B Iacopetta
Journal:  Oncology       Date:  2000       Impact factor: 2.935

7.  Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy.

Authors:  A Hemminki; J P Mecklin; H Järvinen; L A Aaltonen; H Joensuu
Journal:  Gastroenterology       Date:  2000-10       Impact factor: 22.682

8.  Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level.

Authors:  W S Samowitz; K Curtin; K N Ma; D Schaffer; L W Coleman; M Leppert; M L Slattery
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-09       Impact factor: 4.254

9.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

Authors:  Christine M Ribic; Daniel J Sargent; Malcolm J Moore; Stephen N Thibodeau; Amy J French; Richard M Goldberg; Stanley R Hamilton; Pierre Laurent-Puig; Robert Gryfe; Lois E Shepherd; Dongsheng Tu; Mark Redston; Steven Gallinger
Journal:  N Engl J Med       Date:  2003-07-17       Impact factor: 91.245

10.  Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer.

Authors:  David Fallik; Francesco Borrini; Valérie Boige; Jérôme Viguier; Sandrine Jacob; Catherine Miquel; Jean-Christophe Sabourin; Michel Ducreux; Françoise Praz
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701
View more
  2 in total

1.  The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program.

Authors:  Aparna Mukherjee; Thomas J McGarrity; Francesca Ruggiero; Walter Koltun; Kevin McKenna; Lisa Poritz; Maria J Baker
Journal:  Hered Cancer Clin Pract       Date:  2010-11-22       Impact factor: 2.857

2.  Secondary Prevention of Colorectal Cancer: Is There an Optimal Follow-up for Patients with Colorectal Cancer?

Authors:  John M Carethers
Journal:  Curr Colorectal Cancer Rep       Date:  2010-01-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.